# Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC

> **NCT06739928** · PHASE2 · RECRUITING · sponsor: **Guangzhou Institute of Respiratory Disease** · enrollment: 120 (estimated)

## Conditions studied

- Small Cell Lung Cancer Extensive Stage

## Interventions

- **DRUG:** Irinotecan liposome (II) combined with adebrelimab and carboplatin
- **DRUG:** etoposide combined with adebrelimab and carboplatin

## Key facts

- **NCT ID:** NCT06739928
- **Lead sponsor:** Guangzhou Institute of Respiratory Disease
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06739928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06739928, "Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06739928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*